Neuroprotective properties of a novel, non-haematopoietic agonist of the erythropoietin receptor

Brain

Volumn 133, Issue 8, 2010, Pages 2281-2294

  Pankratova, Stanislava ^a   Kiryushko, Darya ^a   Sonn, Katrin ^b   Soroka, Vladislav ^a   Køhler, Lene B ^a   Rathje, Mette ^a   Gu, Bing ^a   Gotfryd, Kamil ^a   Clausen, Ole ^a   Zharkovsky, Alexander ^b   Bock, Elisabeth ^a   Berezin, Vladimir ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Faculty of Medicine   (Estonia)

Author keywords

Erythropoietin; Kainic acid; Neurite outgrowth; Neuroprotection; Peptide mimetic

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; EPOTRIS; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT;

ALPHA HELIX; ANIMAL CELL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CELL SURVIVAL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EMBRYO; ERYTHROCYTE COUNT; ERYTHROPOIESIS; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MORTALITY; MOUSE; NERVE CELL; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVE FIBER GROWTH; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CAPILLARY PERMEABILITY; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; GENE SILENCING; GENETICS; METABOLISM; NEURITE; NEURODEGENERATIVE DISEASES; PHYSIOLOGY; SEIZURES; WISTAR RAT;

ANIMALS; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; CELLS, CULTURED; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEURITES; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; RECEPTORS, ERYTHROPOIETIN; SEIZURES;

EID: 77957097611     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq101     Document Type: Article

References (60)

1. Ambjorn M, Asmussen JW, Lindstam M, Gotfryd K, Jacobsen C, Kiselyov VV, et al. Metallothionein and a peptide modeled after metallothionein, EmtinB, induce neuronal differentiation and survival through binding to receptors of the low-density lipoprotein receptor family. J Neurochem 2008; 104: 21-37.
2. Ben-Ari Y. Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy. Neuroscience 1985; 14: 375-403.
3. Benkovic SA, O'Callaghan JP, Miller DB. Regional neuropathology following kainic acid intoxication in adult and aged C57BL/6J mice. Brain Res 2006; 1070: 215-231.
4. Bocker-Meffert S, Rosenstiel P, Rohl C, Warneke N, Held-Feindt J, Sievers J, et al. Erythropoietin and VEGF promote neural outgrowth from retinal explants in postnatal rats. Invest Ophthalmol Vis Sci 2002; 43: 2021-2026.
5. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006; 3: CD003407.
6. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005; 6: 484-494.
7. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, et al. Erythropoietin mediates tissue protection through an erythropoietin and common b-subunit heteroreceptor. Proc Natl Acad Sci USA 2004; 101: 14907-14912.
8. Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 2008; 105: 10925-10930.
9. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000; 97: 10526-10531.
10. Byts N, Samoylenko A, Fasshauer T, Ivanisevic M, Hennighausen L, Ehrenreich H, et al. Essential role for Stat5 in the neurotrophic but not in the neuroprotective effect of erythropoietin. Cell Death Differ 2008; 15: 783-792.
11. Callebaut I, Labesse G, Durand P, Poupon A, Canard L, Chomilier J, et al. Deciphering protein sequence information through hydrophobic cluster analysis (HCA): current status and perspectives. Cell Mol Life Sci 1997; 53: 621-645.
12. Chen ZY, Warin R, Noguchi CT. Erythropoietin and normal brain development: receptor expression determines multi-tissue response. Neurodegener Dis 2006; 3: 68-75.
13. Chu K, Jung KH, Lee ST, Kim JH, Kang KM, Kim HK, et al. Erythropoietin reduces epileptogenic processes following status epilepticus. Epilepsia 2008; 49: 1723-1732.
14. D'Mello SR, Galli C, Ciotti T, Calissano P. Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by insulin-like growth factor I and cAMP. Proc Natl Acad Sci USA 1993; 90: 10989-10993.
15. Davis JM, Arakawa T, Strickland TW, Yphantis DA. Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry 1987; 26: 2633-2638.
16. Deechongkit S, Aoki KH, Park SS, Kerwin BA. Biophysical comparability of the same protein from different manufacturers: a case study using Epoetin alfa from Epogen® and Eprex®. J Pharm Sci 2006; 95: 1931-1943.
17. Ehrenreich H, Degner D, Meller J, Brines M, Behe M, Hasselblatt M, et al. Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry 2004; 9: 42-54.
18. Elliott S, Lorenzini T, Chang D, Barzilay J, Delorme E. Mapping of the active site of recombinant human erythropoietin. Blood 1997; 89: 493-502.
19. Erbayraktar S, Grasso G, Sfacteria A, Xie QW, Coleman T, Kreilgaard M, et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 2003; 100: 6741-6746.
20. Hansen RK, Christensen C, Korshunova I, Kriebel M, Burkarth N, Kiselyov VV, et al. Identification of NCAM-binding peptides promoting neurite outgrowth via a heterotrimeric G-protein-coupled pathway. J Neurochem 2007; 103: 1396-1407.
21. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-1260.
22. Kaushansky K. Hematopoietic growth factor mimetics. Ann N Y Acad Sci 2001; 938: 131-138.
23. Kawakami M, Sekiguchi M, Sato K, Kozaki S, Takahashi M. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem 2001; 276: 39469-39475.
24. 2+ signaling in neurons induced by the S100A4 protein. Mol Cell Biol 2006; 26: 3625-3638.
25. Kneller DG, Cohen FE, Langridge R. Improvements in protein secondary structure prediction by an enhanced neural network. J Mol Biol 1990; 214: 171-182.
26. Kolkova K, Novitskaya V, Pedersen N, Berezin V, Bock E. Neural cell adhesion molecule-stimulated neurite outgrowth depends on activation of protein kinase C and the Ras-mitogen-activated protein kinase pathway. J Neurosci 2000; 20: 2238-2246.
27. Konishi Y, Chui DH, Hirose H, Kunishita T, Tabira T. Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res 1993; 609: 29-35.
28. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004; 305: 239-242.
29. Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 1996; 273: 464-471.
30. Maar TE, Ronn LC, Bock E, Berezin V, Moran J, Pasantes-Morales H, et al. Characterization of microwell cultures of dissociated brain tissue for studies of cell-cell interactions. J Neurosci Res 1997; 47: 163-172.
31. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005; 293: 90-95.
32. Mammis A, McIntosh TK, Maniker AH. Erythropoietin as a neuroprotective agent in traumatic brain injury. Surg Neurol 2009; 71: 527-531.
33. Marti HH. Erythropoietin and the hypoxic brain. J Exp Biol 2004; 207: 3233-3242.
34. Matthews DJ, Topping RS, Cass RT, Giebel LB. A sequential dimerization mechanism for erythropoietin receptor activation. Proc Natl Acad Sci USA 1996; 93: 9471-9476.
35. McCord MC, Lorenzana A, Bloom CS, Chancer ZO, Schauwecker PE. Effect of age on kainate-induced seizure severity and cell death. Neuroscience 2008; 154: 1143-1153.
36. Middleton SA, Barbone FP, Johnson DL, Thurmond RL, You Y, McMahon FJ, et al. Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide. J Biol Chem 1999; 274: 14163-14169.
37. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997; 76: 105-116.
38. Nadam J, Navarro F, Sanchez P, Moulin C, Georges B, Laglaine A, et al. Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus. Neurobiol Dis 2007; 25: 412-426.
39. Neiiendam JL, Kohler LB, Christensen C, Li S, Pedersen MV, Ditlevsen DK, et al. An NCAM-derived FGF-receptor agonist, the FGL-peptide, induces neurite outgrowth and neuronal survival in primary rat neurons. J Neurochem 2004; 91: 920-935.
40. Racine RJ. Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972; 32: 281-294.
41. Ronn LC, Ralets I, Hartz BP, Bech M, Berezin A, Berezin V, et al. A simple procedure for quantification of neurite outgrowth based on stereological principles. J Neurosci Methods 2000; 100: 25-32.
42. Rosenzweig MQ, Bender CM, Lucke JP, Yasko JM, Brufsky AM. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage 2004; 27: 185-190.
43. Ruscher K, Freyer D, Karsch M, Isaev N, Megow D, Sawitzki B, et al. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci 2002; 22: 10291-10301.
44. Sadamoto Y, Igase K, Sakanaka M, Sato K, Otsuka H, Sakaki S, et al. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun 1998; 253: 26-32.
45. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998; 95: 4635-4640.
46. Sanchez PE, Fares RP, Risso JJ, Bonnet C, Bouvard S, Le-Cavorsin M, et al. Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons. Proc Natl Acad Sci USA 2009a; 106: 9848-9853.
47. Sanchez PE, Navarro FP, Fares RP, Nadam J, Georges B, Moulin C, et al. Erythropoietin receptor expression is concordant with erythropoietin but not with common b chain expression in the rat brain throughout the life span. J Comp Neurol 2009b; 514: 403-414.
48. Secher T, Novitskaia V, Berezin V, Bock E, Glenthoj B, Klementiev B. A neural cell adhesion molecule-derived fibroblast growth factor receptor agonist, the FGL-peptide, promotes early postnatal sensorimotor development and enhances social memory retention. Neuroscience 2006; 141: 1289-1299.
49. Siren AL, Fasshauer T, Bartels C, Ehrenreich H. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 2009; 6: 108-127.
50. Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 2001; 98: 4044-4049.
51. Sonn K, Pankratova S, Korshunova I, Zharkovsky A, Bock E, Berezin V, et al. A metallothionein mimetic peptide protects neurons against kainic acid-induced excitotoxicity. J Neurosci Res 2010; 88: 1074-1082.
52. Soroka V, Kiryushko D, Novitskaya V, Ronn LC, Poulsen FM, Holm A, et al. Induction of neuronal differentiation by a peptide corresponding to the homophilic binding site of the second Ig module of the neural cell adhesion molecule. J Biol Chem 2002; 277: 24676-24683.
53. Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 1998; 395: 511-6.
54. Um M, Gross AW, Lodish HF. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal 2007; 19: 634-45.
55. van der Kooij MA, Groenendaal F, Kavelaars A, Heijnen CJ, van Bel F. Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia. Brain Res Rev 2008; 59: 22-33.
56. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003; 198: 971-5.
57. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004; 35: 1732-7.
58. Wen D, Boissel JP, Showers M, Ruch BC, Bunn HF. Erythropoietin structure-function relationships: identification of functionally important domains. J Biol Chem 1994; 269: 22839-46.
59. Xenocostas A, Cheung WK, Farrell F, Zakszewski C, Kelley M, Lutynski A, et al. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol 2005; 61: 189-95.
60. Yu X, Shacka JJ, Eells JB, Suarez-Quian C, Przygodzki RM, Beleslin-Cokic B, et al. Erythropoietin receptor signalling is required for normal brain development. Development 2002; 129: 505-16.